by Stacey Johnson | Aug 2, 2024
He’s back! The regenerative medicine (RM) field’s unofficial mascot – Deadpool – is back in theatres and all over media and social media due to what one must assume is a super(hero)-sized marketing budget. Although some may disagree on his status as a mascot, you...
by Don Gibbons | May 28, 2024
Spinal cord injury (SCI) seemed like a logical first target for pluripotent stem cell therapy. In many cases a discrete lesion blocks the brain’s nerve signals from reaching the muscles or other tissues they are supposed to instruct. The solution: turn stem cells into...
by Lyla El-Fayomi | May 23, 2024
“Regenerative medicine news under the microscope” is a monthly feature highlighting a selection of impactful research findings and headlines across the many subfields of regenerative medicine. I’ve gone slightly longer form with this month’s edition, as I found that...
by Medicine by Design | May 13, 2024
CCRM, the publisher of Signals, has enhanced its long-standing relationship with the University of Toronto’s Medicine by Design through a new strategic alliance. This profile is one in a series of profiles that feature “people” of Medicine by Design. Some minor edits...
by Medicine by Design | Apr 29, 2024
CCRM, the publisher of Signals, has enhanced its long-standing relationship with the University of Toronto’s Medicine by Design through a new strategic alliance. This profile is one in a series of profiles that feature “people” of Medicine by Design. Some minor edits...
by Stacey Johnson | Feb 23, 2024
As a fair-skinned, freckled person (my mom says she painted them on me while I slept), and one who has a family history of skin cancers and melanoma, the news on February 19 that Iovance Biotherapeutics’ AMTAGVITM received U.S. Food and Drug Administration (FDA)...
Comments